53). Starting from observations in preclinical studies, which revealed an association between response to antiangiogenic drugs and the glycolytic activity of tumours or the activity of the liver kinase B1 (LKB1)/AMPK pathway (Refs 54, 55), the authors performed immunohistochemical and digital pathology analyses on specimens derived from relapsed GBM patients, treated or not with regorafenib. The gene discussed is PRKAA2; the disease is glioblastoma.